Asensus Surgical enters a non-binding LOI for potential acquisition by KARL STORZ SE at $0.35 per share, with a $20M bridge loan during a ten-week exclusivity period.

Medical device company Asensus Surgical (ASXC) has entered into a non-binding letter of intent with medical technology firm, KARL STORZ SE & Co. KG, for potential acquisition. Under the agreement, KARL STORZ proposes to acquire Asensus for $0.35 per share in cash, and a merger agreement is expected to be finalized during the exclusivity period of up to ten weeks. Asensus will receive a $20 million bridge loan from KARL STORZ during the exclusivity period for immediate financial obligations.

April 03, 2024
8 Articles

Further Reading